Clinical Trial

Study to Evaluate D-1553 in Subjects With Solid Tumors

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a phase 1/2, open label study of D-1553 single agent and combination treatment to assess the safety and tolerability, identify the MTD and RP2D, evaluate the PK properties and antitumor activities in subjects with advanced or metastatic solid tumor with KRasG12C mutation.
Protocol Amendment History 15 amendments
This ClinicalTrials.gov record has been amended 15 times since 2020-10-10; most recent amendment 2025-03-13.
Status change: Recruiting → Active, Not Recruiting 2024-01-04
Status change: Not Yet Recruiting → Recruiting 2021-03-09
Trial Details
NCT Number NCT04585035
Lead Sponsor InventisBio Co., Ltd
Collaborators: Merck Sharp & Dohme LLC
Conditions Solid Tumor, Adult, NSCLC, CRC
Enrollment 180 participants
Start Date 2020-10-02
Primary Completion 2024-04-30 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2025-03-18